Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T
Conclusion: Compared with 177Lu-PSMA I&T, 19F/177Lu-rhPSMA-7.3 can be considered a suitable candidate for clinical translation because it has similar clearance kinetics and a similar radiation dose to healthy organs but superior tumor uptake and retention. Preliminary treatment experiments showed a favorable antitumor response.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Yusufi, N., Wurzer, A., Herz, M., DAlessandria, C., Feuerecker, B., Weber, W., Wester, H.-J., Nekolla, S., Eiber, M. Tags: Basic Science Investigations Source Type: research
More News: Cancer | Cancer & Oncology | Nuclear Medicine | Prostate Cancer | Science | Urology & Nephrology